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ABSTRACT 
Objectives 
To study the prevalence and risk factors for cardiac autonomic 
neuropathy (CAN) and the utility of prolongation of corrected QT interval 
(QTc) in the ECG to diagnose CAN in patients with diabetes mellitus.  
 
Design and setting 
Cross-sectional study conducted among 100 patients attending the 
diabetic clinic of K.A.P.V. Govt. Medical College, Trichy. 
 
Methods 
The prevalence of CAN among 100 patients with type 2 diabetes 
mellitus was assessed by the five autonomic function tests by Ewing’s 
methodology. The CAN score in each patient and its relationship to the QTc 
interval were analysed. Possible influences of duration of diabetes and heart 
rate variability on the occurrence of CAN also were studied.  
 
Results 
The prevalence of CAN was 58 %.Significant risks for CAN among 
patients with type 2 diabetes were prolonged QTc , reduced heart rate 
variability and disease duration over 10 years . Disease duration over 10 years 
resulted in QTc prolongation in a significant numbers of cases with type 2 
diabetes. The sensitivity, specificity and positive predictive value of QTc 
prolongation for the diagnosis of CAN were77%, 81% and 93.85% 
respectively. Higher CAN scores correlated with longer QTc intervals 
(p<0.001). 
 
Conclusions 
The prevalence of CAN in diabetes mellitus is high. Longer duration of 
diabetes is a significant risk factor. QTc interval in the ECG can be used to 
diagnose CAN with reasonable sensitivity, specificity and positive predictive 
value. 

  
ABBREVIATIONS 
 
ACE  - Angiotensin Converting Enzyme 
ANS  - Autonomic Nervous System 
BP  - Blood Pressure 
CAN  - Cardiovascular Autonomic Neuropathy 
CI  - Confidence Interval 
DAN  - Diabetic Autonomic Neuropathy 
ECG  - Electro Cardio Gram 
E:I Ratio - Expiration-to-Inspiration Ratio 
HDL  - High Density Lipoprotein 
HRV  - Heart Rate Variability 
LDL  - Low Density Lipoprotein 
LV  - Left Ventricle 
LVDD - Left Ventricular Diastolic Dysfunction 
MI  - Myocardial Infarction 
MIBG  - Metaiodo Benzyl Guanidine 
OH  - Orthostatic Hypertension 
CONTENTS 
S. No. Title Page No. 
1. Introduction 1 
2. Aims and Objectives 3 
3. Review of Literature 4 
4. Materials and Methods 31 
5. Observation and Results 36 
6. Discussion 54 
7. Conclusion 59 
 Bibliography  
 Annexure  
  Consent Form  
  Proforma  
  Master Chart  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
  
1 
INTRODUCTION 
 
Patients with diabetes mellitus are at an increased risk of dying from 
cardiovascular diseases, the reason for which is not completely understood. 
Excess cardiovascular risk in this population persists even after normalisation 
for other conventional cardiovascular risk factors (hypertension, dyslipidaemia, 
physical inactivity, smoking) suggesting that there are other incompletely 
understood mechanisms which increase cardiovascular risk in diabetic patients. 
Ventricular instability, as manifested in QT abnormalities, might be an 
important additional mechanism. 
The electrocardiographic QT interval has been extensively studied in 
ischaemic heart disease. Recently, there has been increasing interest in the 
relationship between diabetes and QT abnormalities. QT prolongation and 
increased QTd have been shown to predict cardiac death in both type 1 and 
type 2 diabetes mellitus. Although there is general agreement that QT interval 
is affected by cardiac ischaemia, the effect of hyperglycaemia on QT measures 
is controversial. First, there is controversy as to whether the measure has any 
physiological meaning; secondly, there is no universally accepted method of 
measurement and hence no consensus about the upper limit of normal. 
Nevertheless, several studies have shown increased QT in diabetic 
patients suggesting that assessment of the QT interval could be a cost effective 
way of stratifying such patients according to cardiovascular risk so that 
aggressive treatment could be directed appropriately to improve outcome. 
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In 1980, for the first time, an association of prolonged QTc interval with 
cardiac autonomic neuropathy was given, thereby opening the possibility of a 
rapid objective method for detecting cardiac autonomic neuropathy. Further 
studies demonstrated an association of prolonged QTc interval with cardiac 
dysautonomia in diabetes mellitus. 
This study is performed to estimate the Prevalence of Cardiovascular 
Autonomic Neuropathy with relation to duration of diabetes in our GH and to 
check the accuracy of corrected QT interval in diagnosing it.  
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AIMS AND OBJECTIVES 
 
1. To evaluate the prevalence of Cardiovascular Autonomic Neuropathy in 
Type 2 Diabetes patients in our hospital. 
2. To correlate the prevalence of Cardiovascular Autonomic Neuropathy with 
duration of diabetes. 
3. To evaluate the relationship between Cardiac Autonomic Neuropathy and 
QTc interval prolongation. 
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REVIEW OF LITERATURE 
 
The autonomic nervous system modulates the electrical and contractile 
activity of the myocardium via the interplay of sympathetic and 
parasympathetic activity. An imbalance of autonomic control is implicated in 
the pathophysiology of arrhythmogenesis. Cardiovascular autonomic 
neuropathy (CAN), a common form of autonomic dysfunction found in patients 
with diabetes mellitus, causes abnormalities in heart rate control, as well as 
defects in central and peripheral vascular dynamics. Individuals with 
parasympathetic dysfunction have a high resting heart rate most likely because 
of vagal neuropathy that results in unopposed increased sympathetic outflow. 
Persons with a combined parasympathetic /sympathetic dysfunction have 
slower heart rates. With advanced nerve dysfunction, heart rate is fixed. Thus, 
it is apparent that the determination of heart rate itself is not a reliable 
diagnostic sign of CAN. Reduction in variability of heart rate is the earliest 
indicator of CAN. Clinical manifestations of CAN include exercise intolerance, 
intraoperative cardiovascular lability, orthostatic hypotension (OH), asymptomatic 
ischemia, painless myocardial infarction (MI), and increased risk of mortality. 
A recent publication by the American Diabetes Association highlighted the 
significance of diabetic neuropathy by issuing a statement for healthcare 
professionals that provides guidelines for prevention, detection, and 
management of neuropathy. 
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Cardiovascular autonomic neuropathy (CAN) is a common form of 
autonomic neuropathy, causing abnormalities in heart rate control and central 
and peripheral vascular dynamics. Cardiovascular autonomic neuropathy has 
been linked to postural hypotension, exercise intolerance, enhanced 
intraoperative cardiovascular lability, increased incidence of asymptomatic 
ischemia, myocardial infarction, and decreased likelihood of survival after 
myocardial infarction. Cardiovascular autonomic neuropathy occurs in ~17% 
of patients with type 1 diabetes and 22% of those with type 2. An additional 
9% of type 1 patients and 12% of type 2 patients have borderline dysfunction. 
Cardiac Autonomic Neuropathy 
Perhaps one of the most overlooked of all serious complications of 
diabetes is CAN1.  CAN results from damage to the autonomic nerve fibers that 
innervate the heart and blood vessels and results in abnormalities in heart rate 
control and vascular dynamics2. Reduced heart rate variation is the earliest 
indicator of CAN3. 
In a review of several epidemiological studies among individuals have 
demonstrated that the 5-year mortality rate is five times higher for individuals 
with CAN than for individuals without cardiovascular autonomic involvement4. 
Clinical manifestations of Cardiac Autonomic Neuropathy 
Exercise intolerance 
Autonomic dysfunction can impair exercise tolerance5. Kahn et al.6 
have shown a reduced response in heart rate and blood pressure during exercise 
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in individuals with CAN.  In the study done by Roy et al.7 there was a decrease 
in cardiac output in response to exercise in individuals with CAN.  The severity 
of CAN has also been shown to correlate inversely with an increase in heart 
rate at any time during exercise and with the maximal increase in heart rate. It 
is also noted that decreased ejection fraction, systolic dysfunction, and diastolic 
filling will limit exercise tolerance8. Given the potential for impaired exercise 
tolerance, it has been suggested that diabetic patients who are likely to have 
CAN have cardiac stress testing before undertaking an exercise program9. 
 
Intraoperative cardiovascular liability 
Hemodynamic changes occur during surgery for individuals with and 
without diabetes. A study done by Burgos et al.10 showed that vasopressor 
support was needed more often in diabetic individuals with autonomic 
dysfunction than in those without. The normal autonomic response of 
vasoconstriction and tachycardia did not completely compensate for the 
vasodilating effects of anesthesia. A study done by Kitamura et al.11 also 
recently demonstrated an association between CAN and more severe intraoperative 
hypothermia. Complications arising from intraoperative hypothermia include 
decreased drug metabolism and impaired wound healing. Sobotka et al.12 in his 
study showed that some diabetic patients with autonomic neuropathy have a 
reduced hypoxic-induced ventilatory drive. These data suggest that 
preoperative cardiovascular autonomic screening may provide useful 
information for anesthesiologists planning the anesthetic management of 
diabetic patients and identify those at greater risk for intraoperative complications. 
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Orthostatic hypotension 
In patients with diabetes, orthostatic hypotension is usually due to 
damage to the efferent sympathetic vasomotor fibers, particularly in the 
splanchnic vasculature14. In addition, there is a decrease in cutaneous, 
splanchnic and total vascular resistance that occurs in the pathogenesis of this 
disorder. 
Normally, in response to postural change there is an increase in plasma 
norepinephrine.  For individuals with orthostatic hypotension, there may be a 
reduction in this response relative to the fall in blood pressure15. Diminished 
cardiac acceleration and cardiac output, particularly in association with 
exercise, may also be an important mechanism. Less frequently, there is a rise 
in norepinephrine that may be due to low blood volume or reduced red cell 
mass. Frequently, there are fluctuations in the degree of orthostatic 
hypotension. This may reflect postprandial blood pooling, the hypotensive role 
of insulin, and changing patterns of fluid retention due to renal failure or 
congestive heart failure. 
Patients with orthostatic hypotension typically present with 
lightheadedness and presyncopal symptoms. Symptoms such as dizziness, 
weakness, fatigue, visual blurring, and neck pain also may be due to orthostatic 
hypotension. Many patients, however, remain asymptomatic despite significant 
falls in blood pressure.  If the cause of orthostatic hypotension is CAN, 
treatment goals should not only consist of therapies to increase the standing 
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blood pressure, balanced against preventing hypertension in the supine 
position, but should also provide education to patients so that they avoid 
situations (e.g., vasodilation from hot showers) that result in the creation of 
symptoms (i.e., syncopal episodes).  Such symptoms can result in injuries from 
falling. Cardiovascular autonomic function testing may help differentiate CAN 
from other causes of weakness, lightheadedness, dizziness, or fatigue and 
promote appropriate therapeutic intervention. 
 
Silent myocardial ischemia / cardiac denervation syndrome 
The cause of silent myocardial ischemia in diabetic patients is 
controversial. It is clear, however, that a reduced appreciation for ischemic pain 
can impair timely recognition of myocardial ischemia or infarction and thereby 
delay appropriate therapy. 
12 cross-sectional studies, comparing the presence of silent myocardial 
ischemia, generally measured by exercise stress testing between diabetic 
individuals with and without CAN were analysed. Of the 12 studies, 5 showed 
a statistically significant increased frequency of silent myocardial ischemia in 
individuals with CAN compared with individuals without CAN.  Via meta-
analysis, the Mantel-Haenszel estimate for the pooled prevalence rate risk for 
silent myocardial ischemia was 1.96, with a 95% CI of 1.53–2.51 (P < 0.001;  
n = 1,468 total subjects). These data demonstrate a consistent association 
between CAN and the presence of silent myocardial ischemia. 
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A study done by Ambepityia et al.16 measured the anginal perceptual 
threshold (i.e., the time from onset of 0.1 mV ST depression to the onset of 
angina pectoris during exercise) in individuals with and without diabetes. The 
perception of angina was severely impaired in the diabetic patients, allowing 
these individuals to exercise longer after the onset of myocardial ischemia. The 
delay in perception of angina was associated with the presence of 
cardiovascular autonomic dysfunction. The investigators suggested that the 
neuropathic damage to the myocardial sensory afferent fibers in the autonomic 
nerve supply reduced the diabetic individual’s sensitivity to regional ischemia 
by interrupting pain transmission. Marchant et al.17 examined 22 diabetic and 
30 nondiabetic individuals who had similar left ventricular function and 
severity of coronary artery disease as assessed by coronary angiography and 
ventriculography. The following autonomic function tests were included: heart 
rate variation during deep breathing (beats/min), 30:15 ratio, Valsalva 
maneuver, blood pressure response to standing, and blood pressure response to 
sustained handgrip. All 52 individuals manifested ischemia during exercise. A 
total of 16 individuals did not experience angina, and 10 of these had diabetes. 
Comparing the silent ischemia group (n = 16) with the group who did 
experience angina (n = 36) revealed impaired autonomic function in the silent 
ischemia group, with statistically lower 30:15 ratios. Hikita et al.18, used 24-h 
ambulatory ECG recordings and demonstrated that HRV is reduced in diabetic 
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patients with silent ischemia when compared with nondiabetic individuals with 
silent or painful ischemia. 
The presence of CAN does not exclude painful myocardial infarction 
(MI) among individuals with diabetes19. Chest pain in any location in a patient 
with diabetes should be considered to be of myocardial origin until proven 
otherwise; but, of equal importance, unexplained fatigue, confusion, tiredness, 
edema, hemoptysis, nausea and vomiting, diaphoresis, arrhythmias, cough, or 
dyspnea should alert the clinician to the possibility of silent MI. 
 
Increased risk of mortality 
In a study done by Ewing et al.20 the 2.5-year mortality rate of 27.5% 
increased to 53% after 5 years in diabetic patients with abnormal autonomic 
function tests compared with a mortality rate of only 15% over the 5-year 
period among diabetic patients with normal autonomic function test results. It 
is also noted that half of the deaths in individuals with abnormal autonomic 
function tests were from renal failure, and 29% were from sudden death. This 
study also revealed that symptoms of autonomic neuropathy, especially 
postural hypotension, and gastric symptoms in the presence of abnormal 
autonomic function tests carried a particularly poor prognosis. 
A study by O’Brien21  reported 5-year mortality rates of 27% in patients 
having asymptomatic autonomic neuropathy compared with an 8% mortality 
rate in diabetic subjects with normal autonomic function tests. 
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Rathmann et al.22 designed a study to assess the risk of mortality due to 
CAN among patients with CAN but without a clinical manifestation of severe 
complications (proteinuria, proliferative retinopathy, coronary artery disease, or 
stroke) 8 years after their first clinical examination. The mortality of diabetic 
patients with CAN increased steadily over the 8-year period (6% after 2 years, 
14% after 4 years, 17% after 6 years, and 23% after 8 years) compared with an 
age-, sex-, and duration of diabetes-matched control group where there was one 
death. Autonomic dysfunction was found to be an independent risk factor with 
poor prognosis. Some autonomic neuropathic symptoms (orthostatic 
hypotension, gastroparesis, gustatory sweating and erectile impotence) were 
found more frequently among subjects who died. 
A population-based study (the Hoorn study) examined 159 individuals 
with type 2 diabetes (85 had newly diagnosed diabetes) who were followed for 
an average of nearly 8 years. All-cause as well as cardiovascular mortality were 
found to be associated with impaired autonomic function in this study.  The 
investigators also suggested that cardiovascular autonomic dysfunction in 
individuals already at high risk (e.g., those with diabetes, high blood pressure, 
or a history of cardiovascular disease) may be particularly hazardous24. 
Potential reasons for the increased mortality rate associated with CAN 
Despite the increased association with mortality, the causative 
relationship between CAN and the increased risk of mortality has not been 
conclusively established. Several mechanisms have been suggested including a 
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relationship with autonomic control of respiratory function. Page and Watkins26 
reported 12 cardiorespiratory arrests in eight diabetic individuals with severe 
autonomic neuropathy and suggested that diabetic individuals with CAN have 
impaired respiratory responses to conditions of hypoxia and may be 
particularly susceptible to medications that depress the respiration system. An 
impaired ability to recognize hypoglycemia and impaired recovery from 
hypoglycemic episodes due to defective endocrine counterregulatory 
mechanisms are also potential reasons for death.  Clarke et al.27 speculated that 
the increased mortality found for patients with clinical symptoms of autonomic 
neuropathy were due to both a direct effect of the autonomic neuropathy itself 
and an indirect, but parallel, association with accelerating microvascular 
complications. A study conducted by O’Brien et al. suggested that the high 
rate of mortality due to end-stage renal disease among diabetic patients with 
autonomic neuropathy may have been due to the parallel development of late-
stage neuropathy and nephropathy. The presence of autonomic neuropathy may 
accelerate the rate of progression of diabetic glomerulopathy by mechanisms 
not completely understood.  A consequential increase in cardiovascular risk 
experienced by individuals with nephropathy has also been noted. In one study 
of type 1 diabetic individuals, hypertension along with LDL and HDL 
cholesterol concentrations were found to be independent correlates of CAN28. 
These results suggested that a disturbed cardiovascular risk profile seen in 
individuals with nephropathy might lead to both cardiovascular disease and 
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CAN. Other investigators have also shown independent associations of 
autonomic dysfunction with markers of cardiovascular risk (e.g., elevated 
blood pressure29, body weight, glycosylated hemoglobin, and overt 
albuminuria30). Long-term follow-up studies are needed to distinguish the exact 
roles of cardiovascular risk factors, nephropathy, and CAN in the etiology of 
cardiovascular disease. Nonetheless, CAN cosegregates with indexes of 
macrovascular risk, which may contribute to the marked increase in 
cardiovascular mortality. Diabetic patients with CAN are predisposed to a lack 
of the normal nighttime decrease in blood pressure because of an increased 
prevalence of sympathetic activity31. A disturbed circadian pattern of 
sympathovagal activity with prevalent nocturnal sympathetic activity combined 
with higher blood pressure values during the night and increased left 
ventricular hypertrophy could represent another important link between CAN 
and an increased risk of mortality. 
 
CAN and sudden death 
A number of researchers have reported sudden unexpected deaths 
among subjects identified with autonomic neuropathy. One potential cause of 
sudden death may be explained by severe but asymptomatic ischemia, 
eventually inducing lethal arrhythmias32.  An autonomic imbalance resulting in 
QT prolongation may predispose individuals to life-threatening cardiac 
arrhythmias and sudden death33. Results from the EURODIAB IDDM 
Complications Study showed that male patients with impaired HRV had a 
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higher corrected QT prolongation than males without this complication34. 
Imaging of myocardial sympathetic innervation with various radiotracers (e.g., 
meta-iodobenzylguanidine) has shown that predisposition to arrhythmias and 
an association with mortality may also be related to intracardiac sympathetic 
imbalance35. 
Heart failure is common in individuals with diabetes, identified by the 
presence of neuropathy, even in individuals without evidence of coronary 
artery disease or left ventricular dysfunction36. 
 
Increased mortality after an MI 
Mortality rates after an MI are also higher for diabetic patients than for 
nondiabetic patients. This may be due to autonomic insufficiency, increasing 
the tendency for development of ventricular arrhythmia and cardiovascular 
events after infarction.  Fava et al.37 in his study showed that the presence of 
autonomic neuropathy contributed to a poor outcome in a study of 196 post-MI 
diabetic patients.  Katz et al. showed that a simple bedside test that measured  
1-min HRV during deep breathing was a good predictor of all-cause mortality 
for 185 patients (17.8% with diabetes) after a first MI. 
Dysfunction of the ANS is associated with increased risk of mortality in 
individuals with diabetes. Though the exact pathogenic mechanism is unclear, 
it is realized that some deaths may be avoidable through early identification of 
these higher-risk patients and by slowing, with therapy, the progression of 
autonomic dysfunction and its associated conditions. 
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Association of cerebrovascular disease and CAN 
The frequency of ischemic cerebrovascular events is increased in 
individuals with type 2 diabetes. Toyry et al. examined the impact of 
autonomic dysfunction on the risk of the development of strokes. He followed 
a group of 133 type 2 diabetic patients for 10 years. During the study period, 19 
individuals had one or more strokes. Abnormalities of parasympathetic and 
sympathetic autonomic function were found to be independent predictors of 
stroke in this cohort. 
 
Progression of CAN 
Results of the cardiovascular autonomic function tests that are mediated 
mainly by the parasympathetic nervous system (e.g., heart rate response to deep 
breathing) are typically abnormal before those responses that are mediated by 
the sympathetic nerves. Although one might speculate then that parasympathetic 
damage occurs before sympathetic damage, this may not always be true. The 
increased frequency of abnormalities detected via tests of the parasympathetic 
system may merely be a reflection of the test (e.g., sensitivity) and not of the 
natural history of nerve fiber damage. Thus, it may be better to describe the 
natural history of autonomic dysfunction as developing from early to more 
severe involvement rather than to anticipate a sequence of parasympathetic to 
sympathetic damage. 
Although much remains to be learned about the natural history of CAN, 
previous reports can be coalesced into a few observations that provide some 
insight with regard to progression of autonomic dysfunction: 
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• It can be detected at the time of diagnosis. 
• Neither age nor type of diabetes are limiting factors in its emergence, 
being found in young individuals with newly diagnosed type 1 diabetes 
and older individuals newly diagnosed with type 2 diabetes. 
• Poor glycemic control plays a central role in development and 
progression. 
• Intensive therapy can slow the progression and delay the appearance of 
abnormal autonomic function tests. 
• Subclinical autonomic neuropathy can be detected early using 
autonomic function test. 
• Autonomic features that are associated with sympathetic nervous system 
dysfunction (e.g., orthostatic hypotension) are relatively late 
complications of diabetes. 
• There is an association between CAN and diabetic nephropathy that 
contributes to high mortality rates. 
 
CLINICAL TESTING OF AUTONOMIC FUNCTION 
Assessing cardiovascular autonomic function 
Quantitative tests of autonomic function have historically lagged behind 
measures of motor nerve function and sensory nerve function deficits. The lack 
of interest in the development of such measures was partly due to the erroneous 
but commonly held view that autonomic neuropathy was only a small and 
relatively obscure contributor to the peripheral neuropathies affecting 
individuals with diabetes. 
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In the early 1970s, Ewing et al.38 proposed five simple noninvasive 
cardiovascular reflex tests (i.e., Valsalva maneuver, heart rate response to deep 
breathing, heart rate response to standing up, blood pressure response to 
standing up, and blood pressure response to sustained handgrip) that have been 
applied successfully by many. The clinical literature has consistently identified 
these five tests as they have been widely used in a variety of studies. The tests 
are valid as specific markers of autonomic neuropathy if end-organ failure has 
been carefully ruled out and other potential factors such as concomitant illness, 
drug use (including antidepressants, over-the-counter antihistamines and 
cough/cold preparations, diuretics, and aspirin), lifestyle issues (such as 
exercise, smoking, and caffeine intake), and age are taken into account. A large 
body of evidence indicates that these factors can, to various degrees, affect the 
cardiovascular ANS and potentially other autonomic organ systems. 
Heart rate response to deep breathing is for the most part a function of 
parasympathetic activity, although the sympathetic nervous system may affect 
this measure.  Similarly, it is parasympathetic activity that plays the greatest 
role in the heart rate regulation for short-term standing, where the act of 
standing involves low-level exercise and parasympathetic tone is withdrawn to 
produce a sudden tachycardic response. In response to subsequent underlying 
blood pressure changes while standing, a baroreceptor-mediated reflex involves 
the sympathetic nerves for further heart rate control. Heart rate response to the 
Valsalva maneuver is influenced by both parasympathetic and sympathetic 
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activity. Measurements of blood pressure response to standing and blood 
pressure response to sustained handgrip are used to assess sympathetic activity.  
 
Heart rate response to deep breathing (i.e., beat-to-beat heart rate 
variation, R-R variation) 
 
Beat-to-beat variation in heart rate with respiration depends on 
parasympathetic innervation. Pharmacological blockade of the vagus nerve 
with atropine all but abolishes respiratory sinus arrhythmia, whereas 
sympathetic blockade with the use or pretreatment of propranolol has only a 
slight effect on it. Several different techniques have been described in clinical 
literature, but measurement during paced deep breathing is considered the most 
reliable. The patient lies quietly and breathes deeply at a rate of six breaths per 
minute (a rate that produces maximum variation in heart rate) while a heart 
monitor records the difference between the maximum and minimum heart 
rates. Over a number of years, there have been several different measures of  
R-R variation. The following six measures have most consistently been 
reported (standard deviation, coefficient of variation, mean circular resultant, 
maximum minus minimum, expiration-to-inspiration [E:I] ratio, and spectral 
analysis). There are advantages, disadvantages, and considerations that need to 
be recognized for all of the measures of R-R variation. 
 
Heart rate response to standing 
This test evaluates the cardiovascular response elicited by a change from 
a horizontal to a vertical position. The typical heart rate response to standing is 
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largely attenuated by a parasympathetic blockade achieved with atropine. In 
healthy subjects, there is a characteristic and rapid increase in heart rate in 
response to standing that is maximal at approximately the 15th beat after 
standing. This is followed by a relative bradycardia that is maximal at 
approximately the 30th beat after standing. In patients with diabetes and 
autonomic neuropathy, there is only a gradual increase in heart rate. The patient 
is connected to an electrocardiogram (ECG) monitor while lying down and 
then stands to a full upright position. ECG tracings are used to determine the 
30:15 ratio, calculated as the ratio of the longest R-R interval (found at about 
beat 30) to the shortest R-R interval (found at about beat 15). Because the 
maximum and minimum R-R intervals may not always occur at exactly the 
15th or 30th beats after standing, Ziegler et al.39 redefined the maximum / 
minimum 30:15 ratio as the longest R-R interval during beats 20–40 divided by 
the shortest R-R interval during beats 5–25. 
 
Valsalva maneuver 
The reflex response in healthy subjects to the Valsalva maneuver 
includes tachycardia and peripheral vasoconstriction during strain, followed by 
an overshoot in blood pressure and bradycardia after release of strain. The 
response is mediated through alternating activation of parasympathetic and 
sympathetic nerve fibers. Pharmacological blockade studies using atropine, 
phentolamine (an α-adrenergic antagonist), and propranolol (a nonspecific  
β-adrenergic blocker) confirm dual involvement of autonomic nerve branches 
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for the response to this maneuver by demonstrating the drugs’ varied effects of 
attenuation or augmentation of the hemodynamic response to the maneuver at 
specific times during the response .In patients with autonomic damage from 
diabetes, the reflex pathways are damaged. This is seen as a blunted heart rate 
response and sometimes as a lower-than-normal decline in blood pressure 
during strain, followed by a slow recovery after release. 
In the standard Valsalva maneuver, the supine patient, connected to an 
ECG monitor, forcibly exhales for 15 s against a fixed resistance (40 mmHg) 
with an open glottis. A sudden transient increase in intrathoracic and intra-
abdominal pressures, with a consequent hemodynamic response, results. 
The response to performance of the Valsalva maneuver has four phases 
and in healthy individuals can be observed as follows: 
• Phase I: Transient rise in blood pressure and a fall in heart rate due to 
compression of the aorta and propulsion of blood into the peripheral 
circulation. Hemodynamic changes are mostly secondary to mechanical 
factors. 
• Phase II: Early fall in blood pressure with a subsequent recovery of 
blood pressure later in the phase. The blood pressure changes are 
accompanied by an increase in heart rate. There is a fall in cardiac 
output due to impaired venous return causing compensatory cardiac 
acceleration, increased muscle sympathetic activity, and peripheral 
resistance. 
  
21 
• Phase III: Blood pressure falls and heart rate increases with cessation of 
expiration. 
• Phase IV: Blood pressure increases above the baseline value 
(overshoot) because of residual vasoconstriction and restored normal 
venous return and cardiac output. 
The Valsalva ratio is determined from the ECG tracings by calculating 
the ratio of the longest R-R interval after the maneuver (reflecting the 
bradycardic response to blood pressure overshoot) to the shortest R-R interval 
during or shortly after the maneuver (reflecting tachycardia as a result of 
strain).  
Levitt et al.40 showed that the rate of deterioration of the Valsalva ratio 
was 0.015 per year for individuals with type 1 diabetes, which was more than 
twice that expected from cross-sectional studies of the aging effect in normal 
individuals of a similar age range. 
 
Assessing cardiovascular adrenergic (sympathetic) function 
Systolic blood pressure response to standing 
Blood pressure normally changes only slightly on standing from a sitting 
or supine position. The response to standing is mediated by sympathetic nerve 
fibers. In healthy subjects, there is an immediate pooling of blood in the 
dependent circulation resulting in a fall in blood pressure that is rapidly 
corrected by baroreflex-mediated peripheral vasoconstriction and tachycardia. 
In normal individuals, the systolic blood pressure falls by < 10 mmHg in 30 s. 
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In diabetic patients with autonomic neuropathy, baroreflex compensation is 
impaired. A response is considered abnormal when the diastolic blood pressure 
decreases more than 10 mmHg or the systolic blood pressure falls by 30 mmHg 
within 2 min after standing. A task force of the American Academy of 
Neurology (AAN) and the American Autonomic Society defined orthostatic 
hypotension as a fall in systolic blood pressure of ≥ 20 mmHg or diastolic 
blood pressure of ≥ 10 mmHg accompanied by symptoms41. 
 
Diastolic blood pressure response to sustained handgrip 
In this test, sustained muscle contraction as measured by a handgrip 
dynamometer causes a rise in systolic and diastolic blood pressure and heart 
rate. This rise is caused by a reflex arc from the exercising muscle to central 
command and back along efferent fibers. The efferent fibers innervate the heart 
and muscle, resulting in increased cardiac output, blood pressure, and heart 
rate. The dynamometer is first squeezed to isometric maximum, then held at 
30% maximum for 5 min. The normal response is a rise of diastolic blood 
pressure >16 mmHg, whereas a response of <10 mmHg is considered 
abnormal. Patients with DAN are more likely to exhibit only a small diastolic 
blood pressure rise. 
 
Response to tilting 
The hemodynamic response to standing is a commonly performed 
measure of autonomic function. Passive head-up tilting provides a more precise 
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level of standardization to the orthostatic stimulus and reduces the muscular 
contraction of the legs, which can reduce lower-leg pooling of blood. A tilt 
angle of 60° is commonly used for this test. The tilt may be maintained for 10–
60 min or until the patient’s orthostatic symptoms can be reproduced. The 
orthostatic stress of tilting evokes a sequence of compensatory cardiovascular 
responses to maintain homeostasis. As for the stand response, the normal tilted 
reflex consists of an elevation in heart rate and vasoconstriction. If reflex 
pathways are defective, blood pressure falls markedly with hemodynamic 
pooling. An abnormal response is defined similarly to that associated with 
standing. 
WHO IS A CANDIDATE FOR TESTING? 
Autonomic function tests based on changes in heart rate variation and 
blood pressure regulation can detect cardiovascular complications at early 
stages of involvement in asymptomatic patients. Because late stages of CAN 
are indicators of poor prognosis in diabetic patients, early prognostic 
capabilities offer a significant contribution to diagnosis and subsequent 
therapy. 
Evidence from clinical literature can be found that support 
recommendations for various subpopulations. They include the following. 
Diabetic patients with a history of poor glycemic control 
Long-term poor glycemic control can only increase the risk of 
developing advanced diabetic neuropathy, although long-term follow-up 
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studies are lacking. A 4-year follow-up study done by Mustonen et al.42 of 32 
individuals with type 2 diabetes showed that poor glycemic control was an 
important determinant of the progression of autonomic nerve dysfunction. 
The DCCT provided extensive clinical evidence that good metabolic 
control reduces diabetic complications. Specifically with regard to 
cardiovascular autonomic function, the DCCT showed that intensive glycemic 
control prevented the development of abnormal heart rate variation and slowed 
the deterioration of autonomic dysfunction over time for individuals with type 
1 diabetes. 
Poor glycemic control may also be a consequence of DAN (e.g., 
gastroparesis that goes unidentified). Treatment of gastro intestinal dysfunction 
often improves glycemic control. 
 
Diagnosed diabetic patients 
Primary prevention of diabetes is the absolute goal.  It has been shown 
that lifestyle intervention can reduce the incidence of type 2 diabetes. 
Individuals that do develop diabetes, however, are likely to suffer from its 
complications. In fact, researchers have confirmed the presence of autonomic 
neuropathy at presentation. In its entirety, the evidence supports the contention 
that all patients with diabetes, regardless of metabolic control, are at risk for 
autonomic complications. Given that CAN may be life-threatening and the 
assessment for its presence can be easily performed, testing for cardiovascular 
autonomic dysfunction is suggested for individuals with diabetes. This includes 
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testing to identify children and adolescents with autonomic neuropathy.  
Massin et al.43 in his study demonstrated that early puberty is a critical period 
for the development of CAN and suggested that all type 1 diabetic patients 
should be screened for CAN beginning at the first stage of puberty. 
 
MANAGEMENT IMPLICATIONS OF CARDIOVASCULAR 
AUTONOMIC NEUROPATHY 
Treatment Interventions for Orthostatic Hypotension 
Treatment of orthostatic hypotension comprises nonpharmacological 
and pharmacological measures. Nonpharmacological measures such as 
increasing consumption of water44 and the use of lower-extremity stockings to 
reduce symptoms (eg, dizziness, dyspnea) should be encouraged when treating 
orthostatic hypotension attributable to autonomic dysfunction. Pharmacological 
therapies must balance an increase in standing BP against prevention of supine 
hypotension. Orthostatic hypotension can be aggravated by different forms of 
therapy (eg, tricyclic antidepressant [amitriptyline]) used for the treatment of 
other complications (eg, painful sensory neuropathy). Therefore, careful 
attention to other medications that may aggravate orthostatic hypotension in 
these patients is mandatory.45 Recently, some novel approaches using other 
pharmacological agents have been investigated in nondiabetic individuals with 
orthostatic symptoms. Enhancement of ganglionic transmission via the use of 
pyridostigmine (inhibitor of acetylcholinesterase) improved symptoms and 
orthostatic BP with only modest effects in supine BP for 15 patients with 
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POTS.89 Similarly, the use of β-adrenergic blockers may benefit the 
tachycardia and anticholinergics, the orthostatic bradycardia. Pyridostigmine 
has also been shown to improve HRV in healthy young adults.46 Fluoxetine, a 
selective serotonin reuptake inhibitor, improved hemodynamic parameters and 
symptoms of orthostatic hypotension in patients with Parkinson disease.47 In 
patients with pooling of blood in the splanchnic bed, somatostatin may be of 
value, and in patients with contracted plasma volume, treatment with 
erythropoietin is recommended. 
 
Management of Exercise Intolerance 
In diabetic individuals with CAN, exercise tolerance is limited as a 
result of impaired parasympathetic / sympathetic responses that would 
normally enhance cardiac output and direct peripheral blood flow to skeletal 
muscles.  Reduced ejection fraction, systolic dysfunction, and a decrease in the 
rate of diastolic filling also limit exercise tolerance.  In diabetic patients 
without evidence of heart disease but with asymptomatic vagal CAN, exercise 
capacity (greatest tolerable workload and maximal oxygen uptake), heart rate, 
BP, cardiac stroke volume, and hepatosplanchnic vascular resistance are 
diminished. A further decrease in exercise capacity and BP is seen in patients 
with both vagal CAN and orthostatic hypotension. The severity of CAN 
correlates inversely with the increase in heart rate at any time during exercise 
and with the maximal increase in heart rate. Thus, CAN contributes to 
diminished exercise tolerance. Therefore, autonomic testing offers a useful tool 
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to identify patients with potentially poor exercise performance and may help 
prevent hazards when patients are introduced to exercise training programs.  
For diabetic persons likely to have CAN, it has been suggested that cardiac 
stress testing should be performed before beginning an exercise program. 
When discussing exercise instructions and goals with patients with CAN, 
health care providers need to emphasize that the use of heart rate is an 
inappropriate gauge of exercise intensity, because maximal heart rate is lower 
in persons with CAN. Recently, it has been shown that percent heart rate 
reserve, an accurate predictor of percent VO2 reserve, can be used to prescribe 
and monitor exercise intensity in diabetic individuals with CAN. An alternate 
method for monitoring intensity of physical activity is the rated perceived 
exertion scale. 
 
Perioperative Management 
There is a 2 to 3-fold increase in cardiovascular morbidity and mortality 
intraoperatively for patients with diabetes.  Patients with severe autonomic 
dysfunction have a high risk of BP instability,48 and intraoperative BP support 
is needed more often in those with greater impairment. Intraoperative 
hypothermia (which may decrease drug metabolism and affect wound healing) 
and impaired hypoxic induced ventilatory drive have also been shown to be 
associated with the presence of CAN. Noninvasive diagnostic methods 
assessing autonomic function allow identification of at-risk patients 
preoperatively and may better prepare the anesthesiologist for potential 
hemodynamic changes. 
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Potential for Reversal of CAN 
Several studies have reported that it is possible to improve HRV. In 
patients with minimal abnormalities, endurance training under strict 
supervision and lifestyle intervention associated with weight loss improve 
HRV.  Johnson et al.49 have reported improved LV function in patients with 
diabetic autonomic neuropathy (DAN) by using an aldose reductase inhibitor, 
but this still needs to be shown on a larger scale. Surprisingly, LV ejection 
fractions improved without a change in quantitative autonomic function test 
scores. β-Blockers such as bisoprol improved HRV in heart failure.50  The 
addition of spironolactone to enalapril, furosemide, and digoxin in patients with 
heart failure improved sympathovagal balance.51  Angiotensin-converting 
enzyme (ACE) inhibition with quinapril increases total HRV and improves the 
parasympathetic / sympathetic balance in patients with mild but not advanced 
autonomic neuropathy.52 
ACE inhibition improves the prognosis of chronic heart failure,53 but 
plasma concentrations of angiotensin II remain elevated, which may be related 
to non-ACE pathways that convert angiotensin 1 to angiotensin II. Hence, 
addition of an angiotensin receptor blockade may overcome this problem,54 
ostensibly effecting greater blockade of the renin–angiotensin–aldosterone 
system.  Indeed, there are now several reports of beneficial effects on 
hemodynamic and neurohumoral effects of adding losartan, valsartan, or 
candesartan to an ACE inhibitor. To investigate the effect of ACE inhibition or 
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angiotensin receptor blockade and their combination on both DAN and LVDD 
in asymptomatic patients with diabetes, Didangelos et al.55 examined 62 
patients (34 women) with long-term diabetes mellitus (24 with type 1 diabetes 
mellitus and DAN). 
The patients, who were aged 51.7 ± 13.9 years and were free of 
coronary artery disease and arterial hypertension at baseline, were studied for a  
12-month period. Early ACE inhibition or angiotensin receptor blockade 
improved both DAN and LVDD after 1 year of treatment in asymptomatic 
patients with type 1 or 2 diabetes mellitus. The combination may be slightly 
better than monotherapies on DAN and LVDD, auguring well for the patient 
with established CAN. The clinical importance of these effects should be 
validated by larger studies, however. Improvement in glycemic control reduces 
the incidence of CAN and slows the progression thereof. Glycemic control 
with a reduction of HbA1c from 9.5 to 8.4 has also been shown to improve 
HRV with mild autonomic abnormalities; this was not so in cases of advanced 
autonomic abnormalities.56 
The use of aldose reductase inhibitors such as sorbinil improved resting 
and maximum cardiac output, and epalrestat improved MIBG uptake and HRV 
in patients with mild abnormalities but not in those with advanced CAN.57 The 
most salutary lesson, however, derives from the Steno memorial study by 
Gaede et al.,58 in which intensive multifactorial management aimed at control 
of BP, lipids, HBA1c, use of aspirin, vitamins E and C, and ACE inhibitors 
  
30 
reduced CAN by 68%. Thus, it is important to diagnose CAN because the 
outlook is not as dismal as was once perceived; there are now symptomatic 
therapies that can reorient the functional abnormalities toward improved 
function, as well as therapies that provide prospects for reversal. 
As mentioned previously, clinicians must be careful when giving 
recommendations with regard to exercise for individuals with CAN. This does 
not mean, however, that exercise is inappropriate for individuals with CAN. In 
fact, Howorka et al.59 showed that physical training improved heart rate 
variation in insulin-requiring diabetic individuals with early CAN. Thus, 
careful testing to evaluate cardiovascular autonomic function and its degree of 
development is extremely important. Clinicians working together with the 
patient can develop an appropriate exercise program that will yield a plan for 
reaping maximum benefits. 
  
 
 
 
 
 
 
 
 
MATERIALS AND 
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MATERIALS AND METHODS 
 
STUDY POPULATION 
A total of 100 patients satisfying all the inclusion and exclusion criteria 
were enrolled for the study from the population of Type 2 Diabetes patients 
who attended the out patient clinics and Inpatients of Medicine, K.A.P.V. Govt. 
Medical College and Hospital.  Written consent was obtained from all the 
patients participating in the study after clearly explaining the study procedure. 
Autonomic neuropathy testing by simple bet side tests was done in op 
department and Medical ward using ECG monitor, Pulseoxymeter and BP 
apparatus for the same 100 patients. 
STUDY DURATION 
This study was conducted for a period from May 2010 to August 2011. 
STUDY DESIGN 
A Cross-sectional study to evaluate the Prevalence of Cardiovascular 
Autonomic Neuropathy in Type 2 diabetes and correlate it with duration of 
Diabetes and to investigate the relationship between cardiac autonomic 
dysfunction and corrected QT interval. 
METHODS 
Detailed clinical history was taken from each patients and a complete 
review of their case notes performed. A complete clinical examination of the 
cardiovascular system was done for each patient. 
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Tests for autonomic functions 
On the day of testing patients were instructed not to ingest caffeine 
containing products. All recordings the done 5-8 hours post prandially. Blood 
pressure was recorded manually using standard sphygmomanometer. The heart 
rate variation was calculation using standard Heart rate monitor, Pulseoxymeter 
and continuous ECG recording. A baseline ECG was taken with a Standard 
ECG machine for calculation of QTc interval. The simple bedside tests for 
assessing the autonomic nervous system were described by Ewing and Clarke. 
All patients were subjected to a battery of five tests as described below: 
Heart rate response to valsalva maneuver 
The subject was seated quietly and then asked to blow into the empty 
barrel of a 20ml syringe attached to a mercury sphygmomanometer, to maintain 
a pressure of 40 mm Hg for 10 seconds. The ratio of the maximum heart rate 
during blowing to the minimum during the compensatory bradycardia after 
stopping is calculated. The maneuver was repeated three times with one minute 
interval in between and results were expressed as 
 Valsalva ratio = Max heart rate ÷ Minimum heart rate 
The mean of the three-valsalva ratios was taken as the final value. 
Heart rate variation during deep breathing 
The subject was asked to breathe deeply at six breaths / min (Five 
seconds “in” and five seconds “out”) for one minute. The average heart rate 
difference (maximum minus minimum during the respiratory cycle) is 
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calculated while the patient breaths deeply for 1 min. The results were 
expressed as the mean of the difference between maximum and minimum heart 
rates for the six measured cycles in beats / min. 
 
Immediate heart rate response to standing 
The test was performed with the subject lying quietly on a couch. The 
heart rate increase is recorded 15 seconds after standing from lying position. 
Alternatively, the ratio of the R-R interval of the 30th beat after standing to that 
of the 15th beat (’30:15’) can be calculated. 
Blood pressure response to standing 
This test measured the subject’s blood pressure with a 
sphygmomanometer while he was lying quietly. Then he was made to stand up 
and the blood pressure again after one minute. The postural fall in blood 
pressure was taken as the difference between the systolic pressure lying and the 
systolic pressure standing. The test was in repeated three times and the mean 
systolic blood pressure was calculated. 
Blood pressure response to sustained hand grip 
The blood pressure of the patient was taken three times before the 
maneuver. A modified sphygmomanometer was used to sustain handgrip. The 
patient was asked to grip the inflatable rubber and apply maximum voluntary 
pressure possible. A reading from the attached mercury manometer was taken 
during maximum voluntary contraction. Thereafter, the patient was asked to 
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maintain 30% of maximum voluntary contraction for as long as possible up to 
five minutes. Blood pressure was measured at one minute intervals during the 
handgrip. The result was expressed as the difference between the highest 
diastolic blood pressure during the handgrip exercise and the mean of the three 
diastolic blood pressure readings before the handgrip began. 
The scoring system was done using the following table and results were 
analysed. 
HRV Test BP Test 
Score Deep 
breathing 
Valsalva 
Ratio 
Response 
to 
Standing 
Response 
to 
Handgrip 
Response 
to 
Standing 
0 > 15 > 1.20 > 15 > 15 ≤ 10 
1 11-15 1.1-1.20 12-15 11-15 11-30 
2 ≤ 10 ≤ 1.10 < 12 ≤ 10 > 30 
 
INCLUSION CRITERIA 
Type 2 diabetes already on treatment and newly diagnosed patients. 
EXCLUSION CRITERIA 
1) Age above 60 years 
2) Documented ischaemic heart disease 
3) Documented valvular or congenital heart disease 
4) Hypertension 
5) COPD 
6) Uraemia 
7) Parkinsonism 
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STATISTICAL ANALYSIS 
Statistical analysis was carried out for 100 patients after categorizing 
each variable – Age, sex, duration of diabetes, autonomic function tests, 
autonomic dysfunction score, interpretation results and QTc interval were 
analyzed.  The significance of difference between the proportions was 
indicated by the chi-square (χ2) statistic. The significance of difference in mean 
between the groups was calculated by student t-test. Variables were considered 
to be significant if (P < 0.05). Intervariate analysis was done by using 
Pearson’s r-value correlation. 
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OBSERVATION AND RESULTS 
 
 
 
TABLE - 1 
AGE DISTRIBUTION 
AGE (in Yrs) NUMBER 
21-30 2 
31-40 26 
41-50 56 
>50 16 
 
 
More than half of the study population belongs to the age group of  
41-50 years (56%). 
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FIG. 1 
AGE DISTRIBUTION
2
26
56
16
0
10
20
30
40
50
60
21-30 31-40 41-50 >50
Age
N
u
m
be
r
 
 
  
38 
 
 
 
 
 
TABLE - 2 
SEX DISTRIBUTION 
Sex Number 
Males 56 
Females 44 
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TABLE - 3 
DURATION OF DIABETES 
DURATION OF DIABETES (YRS) NO. 
0-5 56 
6-10 28 
> 10 16 
 
 
More than 50% of the study population has duration of diabetes less 
than 5 years. 
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TABLE - 4 
CARDIOVASCULAR AUTONOMIC DYSFUNCTION - FREQUENCY 
DISTRIBUTION OF NORMAL (0-1), BORDERLINE (2-4), 
ABNORMAL (≥5) – CAN SCORE 
 
CAN SCORE NUMBER 
0-1 58 
2-4 21 
> 5 21 
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FIG. 4 
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TABLE – 5 
HRV TO DEEP BREATHING 
VARIABILITY NUMBER 
< 10 33 
11-15 18 
>15 49 
 
 
Correlation coefficient r = (-0.713) (comparing heart rate variability to deep 
breathing with CAN Score) 
R square = 0.4969 
P < 0.0001 - Highly significant 
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TABLE -6 
HRV TO STANDING 
VARIABILITY NUMBER 
<12 37 
12 - 15 11 
>15 52 
 
Correlation coefficient r = (-0.85) (comparing heart rate variability to standing 
with CAN Score) 
R square = 0.7067 
P < 0.0001 - Highly significant 
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TABLE - 7 
CARDIOVASCULAR AUTONOMIC DYSFUNCTION –  
FREQUENCY DISTRIBUTION OF NORMAL (0-1), 
BORDERLINE (2-4), ABNORMAL (≥5) – COMPARISON WITH 
DURATION OF DIABETES MELLITUS 
 
GROUP 
< 5 Yrs 6-10 Yrs > 10 Yrs CAN SCORE 
n % n % n % 
Statistical 
Interference 
‘p’ 
0-1 40 72 14 50 4 26 0.001 
2-4 11 20 7 25 3 16 0.000 
≥ 5 5 8 7 25 9 58 0.002 
TOTAL 56 100 28 100 16 100 0.001 
 
 
In the study population, the prevalence of definite CAN was 8%, 24% 
and 58% in group A, B and C respectively. The prevalence of definite CAN 
increases with increase in duration of diabetes. P value < 0.001 significant. 
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TABLE - 8 
CORRELATION BETWEEN QTC AND CAN SCORE 
QTc CAN negative CAN Positive 
< 440 61 4 
> 440 18 17 
 
Sensitivity : 77% 
Specificity : 81% 
PPV : 93.85% 
Pearson’s correlation coefficient (r) =0.53 
SIGNIFICANT RELATIONSHIP 
P value: < 0.0001 VERY HIGHLY SIGNIFICANT 
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TABLE – 9 
CORRELATION BETWEEN AUTONOMIC NEUROPATHY (AN) AND 
QTc PROLONGATION IN TOTAL DIABETIC PATIENTS 
 
QTc in 
msec 
Definite 
CAN 
% 
Borderline 
CAN 
% 
No 
CAN 
% ‘p’ Value 
≤ 440 4 20 15 68.8 46 79.5 0.001 
>440 17 80 6 31.2 12 20.5 0.041 
 
 
From the table, QTc interval prolongation occurs with development of 
CAN. Prolongation of QTc interval is well correlated with Cardiac Autonomic 
Neuropathy - P value < 0.001. 
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DISCUSSION 
 
  This study was done in a subgroup of south Indian population to find the 
prevalence of cardiac autonomic neuropathy in diabetic patients and to find out 
the relationship between CAN and prolonged QTc interval. 
 More than half of the study population belongs to the age group of 
41-50 years (56%). 
 There were 56 males and 44 females in the study and there was no 
significant relationship between sex and cardiac autonomic neuropathy. With 
regard to whether either sex is more likely to develop autonomic dysfunction, 
the literature has revealed conflicting reports. For example, in the DCCT, the 
presence of autonomic neuropathy correlated with male sex along with age and 
duration. Jaffe et al.60 show male sex to be predictive of depressed HRV in 
addition to age, duration, and retinopathy. However, in another study of type 1 
diabetic individuals, females along with other parameters (e.g., lipids and 
hypertension) were found to be independent determinants of autonomic 
dysfunction. May et al.61 showed a significantly reduced E:I ratio for females in 
a random sample of 120 type 1 diabetic individuals, along with older age, 
longer duration, and elevated glucose, triglycerides, blood pressure, and urinary 
albumin excretion. 
   In our study those who had diabetes of less than 5 yrs had low 
prevalence of autonomic dysfunction than those who had diabetes for more 
than 10 yrs and there was a significant correlation with the duration of diabetes 
and cardiac autonomic neuropathy. 
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Significant correlations were observed between autonomic neuropathy 
and duration of diabetes (P < 0.0001) in the EURODIAB IDDM complications 
study. 
In our study, there was a negative pearson co efficient between heart rate 
variability and CAN score which was also statistically significant. 
The study done by Arati et al. HRV was measured in 50 diabetic 
subjects and 20 normal subjects in the age group of 50 to 70 years. The result 
showed that diabetic patients had a statistically lower HRV compared to the 
healthy controls. The result correlates with previous studies of Wheeler and 
Watkins in 1973 who observed that diabetics have a marked reduction of HRV 
when compared with normal subjects (Schroeder EB, et al. 2005). This 
observation has been confirmed subsequently by many others (Vinik AI, et al. 
2003). 
Diabetes is an organic disorder in which several of changes takes place 
in the body. The pathophysiology involves almost all the tissues. The 
autonomic nerves being affected by diabetes mellitus shows the signs of 
neuropathy. This could be the cause for the altered autonomic control on the 
heart in chronic diabetics. The lower HRV in severe diabetes could point out at 
the higher neuropathic damage in such patients. Low HRV is reportedly 
associated with cardiovascular morbidity and mortality. Therefore diabetics are 
more susceptible to heart attacks and death due to cardiovascular disorders. 
Schroeder and coworkers investigated the consequence of diabetes and pre 
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diabetic metabolic impairments on the 9 year change in heart rate variability 
and observed that diabetic subjects had a rapid decrease in HRV than non-
diabetic subjects and they also found cross sectional associations between 
decreased HRV and diabetics (Schroeder EB, et al. 2005). 
Measurement of heart rate response to deep breathing may allow 
evaluation of autonomic function in a simple, quick and non-invasive way in 
general practice. 
 In our study there was a significant correlation between prolonged QTc 
interval and cardiac autonomic neuropathy. The Sensitivity was 77%, 
specificity was 81% and the positive predictive value was 93.85%. 
Pappachan J.M. et al.62 studied the utility of prolongation of corrected 
QT interval (QTc) in the ECG to diagnose CAN in patients with diabetes. They 
calculated the sensitivity and specificity of QTc prolongation for the diagnosis 
of CAN were 77% and 62.5% in type 1 and 76.5% and 75% in type 2, 
respectively. They concluded that QTc interval in ECG can be used to diagnose 
CAN with reasonable sensitivity and specificity. This value of sensitivity and 
specificity correlates with our study. 
C.P. Mathur et al.63 studied 50 patients with diabetes with 20 normal 
controls to understand the relationship to CAN with QTc interval. There were 
15 (78.94%) cases with QTc prolongation out of 19 diabetics with CAN. None 
of the diabetics without CAN or control subjects had QTc prolongation. It was 
observed to have sensitivity of 82.6% which is comparable with our study. 
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A Pourmoghaddas, et al.64 found that the prevalence of prolonged QTc 
interval was significantly higher in the case group in comparison with the 
control group, 8 vs. 2% respectively (p value = 0.012, OR = 4.3). 
Abnormality of parasympathetic nervous system is more common than 
(3 fold) abnormality in sympathetic nervous system. 
Mathur et al.65 found that QTc prolongation in diabetic subjects stands 
favourably as an autonomic dysfunction parameter as compared to other ANF 
tests. Further, QTc prolongation has linear positive correlation with the degree 
of CAN. QTc prolongation in diabetics with an otherwise normal heart can be 
used as a diagnostic test for assessment of cardiac autonomic neuropathy and 
may even be considered as a cardiac autonomic function test with prognostic 
significance. 
An association between abnormally prolonged QT interval and syncope, 
malignant ventricular arrhythmias and sudden cardiac death has been found in 
various idiopathic and acquired disorders. QT interval prolongation has been 
implicated in the origin of ventricular arrhythmias, possibly because of less 
uniform recovery of ventricular excitability in the setting of regional 
differences in cardiac sympathetic nervous system activity. 
Hisayoshi Oka et al.66 in 1995, attempted to clarify the relationship of 
the QTc interval to α and β sympathetic as well as parasympathetic function 
tests and concluded that QTc prolongation is an indicator of cardiac 
dysautonomia.and found that the QT interval in diabetics was 420 msec v/s 385 
msec in nondiabetics and thus was significant. 
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LIMITATIONS 
 
There were certain limitations in this study: 
Newer techniques for measuring autonomic functions like the computer 
aided power spectral analysis of heart-rate variability could not be done 
because of limitations in resources and cost. 
There was no facility for measuring Serum Magnesium and Calcium 
which may alter QT interval. 
No Holter monitoring facility was available to assess the risk of 
ventricular tachycardia in patients with QTc prolongation. 
It was not possible to rule out the possibility of congenital long QT 
syndrome. 
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CONCLUSION 
 
The following are the conclusions from this study: 
1. The Prevalence of Cardiovascular Autonomic Neuropathy is high in type 2 
diabetics in our hospital. 
2. The prevalence of CAN will increase with increase in the duration of 
diabetes. About half of the patients with type 2 diabetes have autonomic 
dysfunction after ten years. 
3. There was a significant correlation between reduced heart rate variability 
and cardiac autonomic neuropathy. 
4. A significant correlation is present between Cardiovascular autonomic 
dysfunction and QTc prolongation. QTc interval in the ECG can be used to 
diagnose Cardiovascular autonomic neuropathy with a reasonable 
sensitivity and specificity. 
  
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
  
60 
BIBLIOGRAPHY 
 
1. Maser RE, Lenhard MJ, DeCherney GS:Cardiovascular autonomic 
neuropathy: the clinical significance of its determination. 
Endocrinologist 10:27–33, 2000. 
2. Schumer MP, Joyner SA, Pfeifer MA: Cardiovascular autonomic 
neuropathy testing in patients with diabetes. Diabetes Spectrum 11:227–
231, 1998. 
3. Ziegler D: Diabetic cardiovascular autonomic neuropathy: prognosis, 
diagnosis and treatment. Diabetes Metab Rev 10: 339–383, 1994. 
4. Ziegler D: Cardiovascular autonomic neuropathy: clinical manifestations 
and measurement. Diabetes Reviews 7:300–315, 1999. 
5. Vinik AI, Erbas T: Neuropathy. In Handbook of Exercise in Diabetes. 
Ruderman N., Devlin JT, Schneider SH, Kriska A, Eds. Alexandria, VA, 
American Diabetes Association, p. 463–496, 2002. 
6. Kahn J, Zola B, Juni J, Vinik AI: De-creased exercise heart rate in 
diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 
9:389–394, 1986. 
7. Roy TM, Peterson HR, Snider HL, Cyrus J, et al.: Autonomic influence 
on cardiovascular performance in diabetic subjects.Am J Med 87:382–
388, 1989. 
 
  
61 
8. Vinik AI, Erbas T: Recognizing and treating diabetic autonomic 
neuropathy. Cleve Clin J Med 68:928–944, 2001. 
9. Vinik AI, Erbas T: Neuropathy. In Handbook of Exercise in Diabetes. 
Ruderman N, Devlin JT, Schneider SH, Kriska A, Eds.Alexandria, VA, 
American Diabetes Association,p. 463–496, 2002. 
10. Burgos LG, Ebert TJ, Asiddao C, Turner LA, et al.: Increased 
intraoperative cardiovascular morbidity in diabetics with autonomic 
neuropathy. Anesthesiology, 70:591–597, 1989. 
11. Kitamura A, Hoshino T, Kon T, et al.: Patients with diabetic neuropathy 
are at risk of a greater intraoperative reduction in core temperature. 
Anesthesiology 92:1311–1318, 2000. 
12. Sobotka PA, Liss HP, Vinik AI: Impaired hypoxic ventilatory drive in 
diabetic patients with autonomic neuropathy. J Clin Endocrinol Metab 
62:658–663, 1986. 
13. Low PA, Walsh JC, Huang CY, McLeod JG: The sympathetic nervous 
system in diabetic neuropathy: a clinical and pathological study. Brain 
98:341–356, 1975. 
14. Hilsted J, Parving HH, Christensen NJ, Benn J, Galbo H: Hemodynamics 
in diabetic orthostatic hypotension. J Clin Invest 68:1427–1434, 1981. 
15. Ambepityia G, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis 
AD: Exertional myocardial ischemia in diabetes: a quantitative analysis 
of anginal perceptual threshold and the influence of autonomic function. 
J AmColl Cardiol 15:72–77, 1990. 
 
  
62 
16. Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD: 
Silent myocardial ischemia: role of subclinical neuropathy in patients 
with and without diabetes. J Am Coll Cardiol 22:1433–1437, 1993. 
17. Hikita H, Kurita A, Takase B, Nagayoshi H, Uehata A, Nishioka T, 
Mitani H, Mizuno K, Nakamura H: Usefulness of plasma beta-
endorphin level, pain threshold and autonomic function in assessing 
silent myocardial ischemia in patients with and without diabetes 
mellitus.Am J Cardiol 72:140–143, 1993. 
18. Campbell IW, Ewing DJ, Clarke BF:Painful myocardial infarction in 
severe diabetic autonomic neuropathy. Acta Diabetol Lat 15:210–214, 
1978. 
19. Ewing DJ, Campbell IW, Clarke BF: The natural history of diabetic 
autonomic neuropathy. Q J Med 49:95–108, 1980. 
20. O’Brien IA, McFadden JP, Corrall RJ:The influence of autonomic 
neuropathy on mortality in insulin-dependent diabetes.Q J Med 79:495–
502, 1991. 
21. Rathmann W, Ziegler D, Jahnke M, et al.:Mortality in diabetic patients 
with cardiovascular autonomic neuropathy. Diabet Med 10:820–824, 
1993. 
22. Gerritsen J, Dekker JM, ten Voorde BJ, Kostense PJ, Heine RJ, Bouter 
LM, Heethaar RM, Stehouwer CD: Impaired autonomic function is 
associated with increased mortality, especially in subjects with diabetes, 
hypertension, or a history of cardiovascular disease: the Hoorn Study. 
Diabetes Care 24:1793–1798, 2001. 
 
  
63 
23. Page MM, Watkins PJ: Cardiorespiratory arrest and diabetic autonomic 
neuropathy. Lancet 1:14–16, 1978. 
24. Clarke BF, Ewing DJ, Campbell IW: Diabetic autonomic neuropathy. 
Diabetologia 17:195–212, 1979. 
25. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ: 
Diabetic autonomic neuropathy and cardiovascular risk: Pittsburgh 
Epidemiology of Diabetes Complications Study III. Arch Intern Med 
150:1218–1222, 1990. 
26. Spallone V, Maiello MR, Cicconetti E, Menzinger G: Autonomic 
neuropathy and cardiovascular risk factors in insulin-dependent and non 
insulin-dependent diabetes. Diabetes Res Clin Pract 34 (Suppl. 3):169–
179, 1997. 
27. Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW: Risks for 
sensorimotor peripheral neuropathy and autonomic neuropathy in non-
insulin dependent diabetes mellitus (NIDDM). Muscle Nerve 21:72–80, 
1998. 
28. Menzinger G, Gambardella S, Spallone V: The relationship of 
autonomic neuropathy to other diabetic complications. Diabet Med 10 
(Suppl. 2):74S–76S, 1993. 
29. Rathmann W, Ziegler D, Jahnke M, et al.:  Mortality in diabetic patients 
with cardiovascular autonomic neuropathy. Diabet Med 10:820–824, 
1993. 
 
  
64 
30. Sivieri R, Veglio M, Chinaglia A, et al.: Prevalence of QT prolongation 
in a type 1 diabetic population and its association with autonomic 
neuropathy. Diabet Med 10:920–924, 1993. 
31. Veglio M, Borra M, Stevens LK, Fuller JH, et al.: The relation between 
QTc interval prolongation and diabetic complications: the EURODIAB 
IDDM Complications Study Group. Diabetologia 42:68–75, 1999 
32. Kahn JK, Sisson JC, Vinik AI: Prediction of sudden cardiac death in 
diabetic autonomic neuropathy. J Nucl Med 29:1605–1606, 1988 
33. Stevens MJ, Raffel DM, Allman KC, Dayanikli F, Ficaro E, Sandford T, 
Wieland DM, Pfeifer MA, Schwaiger M:Cardiac sympathetic 
dysinnervation in diabetes: implications for enhanced cardiovascular 
risk. Circulation 98:961–968, 1998. 
34. Johnson BF, Nesto R, Pfeifer M, Slater  W, Vinik A, Wackers F, Young 
L: Systolic and diastolic dysfunction in diabetic patients with 
neuropathy (Abstract). Diabetes 46 (Suppl. 1):314A, 1997. 
35. Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of 
cardiovascular autonomic function tests: 10 years experience in diabetes. 
Diabetes Care 8:491–498, 1985. 
36. Ziegler D, Laux G, Dannehl K, Spuler M, et al.: Assessment of 
cardiovascular autonomic function: age-related normal ranges and 
reproducibility of spectral analysis, vector analysis, and standard tests of 
heart rate variation and blood pressure responses. Diabet Med  
9:166–175, 1992. 
 
  
65 
37. Levitt NS, Stansberry KB, Wynchank S,Vinik AI: The natural 
progression of autonomic neuropathy and autonomic function tests in a 
cohort of people with IDDM. Diabetes Care 19:751–754, 1996. 
38. Position paper: Orthostatic hypotension, multiple system atrophy (the 
Shy Drager syndrome) and pure autonomic failure. J Auton Nerv Syst 
58:123–124, 1996. 
39. Mustonen J, Uusitipa M, Mantysaari M, et al.: Changes in autonomic 
nervous function during the 4-year follow-up in middle-aged diabetic 
and nondiabetic subjects initially free of coronary heart disease. J Intern 
Med 241:227–235, 1997. 
40. Massin MM, Derkenne B, Tallsund M,Rocour-Brumioul D, Ernould C, 
Lebrethon MC, Bourguignon JP: Cardiac autonomic dysfunction in 
diabetic children. Diabetes Care 22:1845–1850, 1999. 
41. Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, Diedrich A, 
Robertson RM, Biaggioni I, Robertson D. The pressor response to water 
drinking in humans: a sympathetic reflex? Circulation. 2000; 101: 504–509. 
42. Vinik A. Diabetic neuropathy: pathogenesis and therapy. Am J Med. 
1999; 107(2B):17S–26S. 
43. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, 
Low PA. Acetylcholinesterase inhibition: a novel approach in the 
treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg 
Psychiatry. 2003;74:1294 –1298. 
 
  
66 
44. Nobrega AC, dos Reis AF, Moraes RS, Bastos BG, Ferlin EL, Ribeiro 
JP. Enhancement of heart rate variability by cholinergic stimulation with 
pyridostigmine in healthy subjects. Clin Auton Res. 2001; 11:11–17. 
45. Moffitt JA, Johnson AK. Short-term fluoxetine treatment enhances 
baroreflex control of sympathetic nervous system activity after hindlimb 
unloading. Am J Physiol Regul Integr Comp Physiol. 2004; 286: R584–R590. 
46. Knuttgen D, Buttner Belz U, Gernot A. Unstable blood pressure during 
anesthesia in diabetic patients with autonomic neuropathy. Anasth 
Intensivther Notfallmed. 1990; 25: 256 –262. 
47. Latson TW, Ashmore TH, Reinhart DJ, Klein KW, Giesecke AH. 
Autonomic reflex dysfunction in patients presenting for elective surgery 
is associated with hypotension after anesthesia induction. Anesthesiology. 
1994; 80: 326 –337. 
48. Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, 
Schabmann A. Effects of physical training on heart rate variability in 
diabetic patients with various degrees of cardiovascular autonomic 
neuropathy. Cardiovasc Res. 1997; 34: 206 –214. 
49. Johnson BF, Law G, Nesto R, Pfeifer M, Slater W, Vinik A, Wackers F, 
Young L. Aldose reductase inhibitor zopolrestat improves systolic 
function in diabetics. Diabetes. 1999; 8(suppl 1):6 –19. 
 
  
67 
50. Pousset F, Copie X, Lechat P, Jaillon P, Boissel JP, Hetzel M, Fillette F, 
Remme W, Guize L, Le Heuzey JY. Effects of bisoprolol on heart rate 
variability in heart failure. Am J Cardiol. 1996; 7:612– 617. 
51. Korkmaz ME, Muderrisoglu H, Ulucam M, Ozin B. Effects of 
spironolactone on heart rate variability and left ventricular systolic 
function in severe ischemic heart failure. Am J Cardiol. 2000; 
6: 649–653. 
52. Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, 
Avramidis MJ, Mayroudi MC, Karamitsos DT. Effect of chronic 
quinapril administration on heart rate variability in patients with diabetic 
autonomic neuropathy. Diabetes Care. 1997; 20:335–361. 
53. Garg R, Yusuf S. Overview of randomized trials of angiotensin 
converting enzyme inhibitors on mortality and morbidity in patients 
with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 
1995; 273:1450 –1456. 
54. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of 
bradykinin-receptor blockade on the response to angiotensin-
convertingenzyme inhibitor in normotensive and hypertensive subjects. 
N Engl J Med. 1998; 339:1285–1292. 
55. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Georga SD, 
Karatzas ND. Effect of quinapril or losartan alone and in combination 
on left ventricular systolic and diastolic functions in asymptomatic 
patients with diabetic autonomic neuropathy. J Diabetes Complications. 
2006; 20:1–7. 
 
  
68 
56. Burger AJ, Weinrauch LA, D’Elia JA, Aronson D. Effects of glycemic 
control on heart rate variability in type I diabetic patients with cardiac 
autonomic neuropathy. Am J Cardiol. 1999; 84: 687– 691. 
57. Ikeda T, Iwata K, Tanaka Y. Long-term effect of epalrestat on cardiac 
autonomic neuropathy in subjects with non-insulin dependent diabetes 
mellitus. Diabetes Res Clin Pract. 1999; 43:193–198. 
58. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial 
intervention in patients with type 2 diabetes mellitus and microalbuminuria: 
the Steno type 2 randomized study. Lancet. 1999; 353: 617– 622. 
59. Howorka K, Pumprla J, Haber P, et al.:Effects of physical training on 
heart rate variability in diabetic patients with various degrees of 
cardiovascular autonomic neuropathy. Cardiovascular Res 34:206–214, 
1997. 
60. Jaffe RS, Aoki TT, Rohatsch, PL, Disbrow EA, Fung DI: Predicting 
cardiac autonomic neuropathy in type 1 (insulin-dependent) diabetes 
mellitus. Clin Auton Res 5: 155-158, 1995. 
61. May O, Arildsen H, Damsgaard EM, Mickley H: Cardiovascular 
autonomic neuropathy in insulin-dependent diabetes mellitus: 
prevalence and estimated risk of coronary heart disease in the general 
population. J Intern Med. 248: 483 – 491, 2000. 
 
  
69 
62. Pappachan J M et al. Cardiac autonomic neuropathy in diabetes mellitus: 
prevalence, risk factors and utility of corrected QT interval in the ECG 
for its diagnosis Postgraduate Medical Journal 2008; 84:205-210. 
63. CP Mathur*, Deepak Gupta**, :QTc Prolongation in Diabetes Mellitus 
– An Indicator of Cardiac Autonomic Neuropathy :JIACM 2006;  
7(2): 130-2 
64. A Pourmoghaddas, A Hekmatnia et al: The relationship between QTc 
interval and cardiac autonomic neuropathy in diabetes mellitus: Mol 
Cell Biochem (2003) 249: 125-8. 
65. Mathur et al: QTc Prolongation in Diabetes Mellitus – An Indicator of 
Cardiac Autonomic Neuropathy. Journal, Indian Academy of Clinical 
Medicine 2006; 7(2): 130-2 
66. Hisayoshi Oka et al – diabetes mellitus proceedings at 14th international 
Federation page 1304(68-71). 
 
 
  
 
 
 
 
 
 
 
 
ANNEXURE 
  
70 
PATIENT CONSENT FORM 
 
STUDY DETAIL: DIAGNOSTIC ACCURACY OF CORRECTED QT 
INTERVAL AS SURROGATE MARKER IN DIABETES 
MELLITUS PATIENTS WITH CARDAC AUTONOMIC 
NEUROPATHY 
 
Study Centre   : Annal Gandhi Memorial Government Hospital,  
 Trichy. 
Name of the patient  :  
Age / Sex   : 
Identification Number :  
Patient / Legal representative may check ( ) these boxes 
• I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask question and all my 
questions and doubts have been answered to my complete 
satisfaction. 
• I understand that my participation in the study is voluntary and 
that I am free to withdraw at any time without giving reason, 
without my legal rights being affected. 
• I understand that sponsor of the clinical study, others working on 
the sponsor’s behalf, the ethical committee and the regulatory 
authorities will not need my permission to look at my health 
records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from 
the study I agree to this access. However, I understand that my 
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identity will not be revealed in any information released to third 
parties or published, unless as required under the law. I agree not 
to restrict the use of any data or results that arise from this study. 
• I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with 
the study team and to immediately inform the study staff if I 
suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms. 
• I hereby consent to participate in this study. 
• I hereby give permission to undergo complete clinical 
examination and diagnostic tests. 
 
Signature / thumb impression of the Patient/Legal Representative: 
Name and Address: 
 
Place:   Date: 
 
Signature of investigator :    
Name  
 
Place:                                 Date: 
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PROFORMA 
 
1. Name    : 
2. Age     : 
3. Sex     : 
4. Address    : 
 
5. OP/IP No.    : 
6. Age of onset of diabetes  : 
7. Duration of diabetes  : 
8. Treatment history   : 
9. H/o smoking   : 
10. H/o alcoholism   : 
11. H/o anginal pain   : 
12. Dietary habits   : 
 
VITALS 
Pulse rate   : / min 
Blood Pressure  :    / mm Hg Limb: RUL / LUL  
Posture   : Standing / Sitting / Supine 
Respiratory rate  : 
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ANTHROPOMETRY 
 Height   : m 
 Weight   : kg 
 BMI    : kg / m2 
CVS     : 
Respiratory system   : 
Abdomen examination  : 
CNS examination   :  
 
TESTS FOR CARDIO VASCULAR AUTONOMIC FUNCTION 
 TEST 1 TEST 2 TEST 3 MEAN 
(i) Valsalva Ratio 
    
(ii) Deep Breathing Test 
    
(iii) Supine to standing 
    
(iv) BP Response to standing 
    
(v) BP Response to sustained 
hand grip     
 
 
ECG  
 QTc     : 
 
  
 
 
 
 
 
 
 
 
MASTER CHART 
  
 
 
S. 
NO. 
ID.N0 
AGE 
(Yrs) 
SEX 
OP/IP 
NO 
DURATION OF 
DIABETES (Yrs) 
PULSE 
RATE (bpm) 
BP (mm Hg ) 
VALSALVA 
RATIO 
HRV TO 
DEEP 
BREATHING 
DIFFERENCE 
HRV FROM 
SUPINE TO 
STANDING 
DIFFERENCE 
BP 
RESPONSE 
TO STANDING 
BP RESPONSE 
TO SUSTAINED 
HAND GRIP 
CAN 
SCORE 
QT c 
1 ABCD 1 46 M 512 4 82 120/80 1.23 94 12 86 4 126/82 124/84 5 424 
2 ABCD 2 55 F 122 5 92 118/70 1.26 105 13 96 4 110/76 100/70 5 452 
3 ABCD 3 35 F 597 2 98 120/76 1.38 105 7 100 2 116/80 124/90 3 442 
4 ABCD 4 57 M 508 6 75 130/80 1.08 81 6 78 3 120/76 140/90 7 448 
5 ABCD 5 59 F 104 20 64 144/66 1.11 68 4 66 2 158/66 150/60 9 462 
6 ABCD 6 45 F 624 15 78 120/60 1.14 86 8 81 3 120/70 128/60 7 448 
7 ABCD 7 52 F 557 2 115 130/80 1.41 131 16 119 4 130/80 140/90 6 454 
8 ABCD 8 54 M 359 2 94 136/84 1.26 105 11 105 11 130/90 148/90 4 426 
9 ABCD 9 60 F 586 1 88 100/50 1.13 98 10 92 4 100/60 110/70 4 416 
10 ABCD 10 51 F 632 13 100 130/90 1.23 112 12 108 8 142/90 144/100 5 448 
11 ABCD 11 56 F 544 6 103 118/80 1.12 110 7 107 4 120/80 120/84 7 458 
12 ABCD 12 47 M 638 12 84 130/90 1.17 90 6 92 8 116/80 140/104 7 462 
13 ABCD 13 42 M 785 6 88 100/70 1.13 97 9 106 18 100/68 110/86 3 448 
14 ABCD 14 33 F 645 3 84 110/74 1.24 98 14 102 18 110/70 120/94 1 412 
15 ABCD 15 48 M 348 5 70 110/70 1.22 88 18 90 20 110/70 120/92 0 422 
16 ABCD 16 44 M 435 9 92 120/74 1.38 99 7 100 8 116/82 124/90 4 422 
17 ABCD 17 55 M 324 4 78 130/80 1.26 96 18 91 13 126/80 140/96 1 418 
18 ABCD 18 44 F 455 15 70 120/80 1.11 74 4 72 2 110/70 130/92 6 416 
19 ABCD 19 42 M 564 3 80 120/70 1.17 96 16 98 18 110/68 124/86 1 426 
20 ABCD 20 42 F 398 8 74 130/82 1.17 90 16 91 17 130/78 130/96 2 442 
21 ABCD 21 48 F 567 5 78 130/80 1.26 96 18 91 13 126/80 140/96 1 432 
22 ABCD 22 36 M 897 12 68 120/70 1.14 76 8 72 4 110/70 120/80 7 452 
23 ABCD 23 58 M 836 7 80 120/70 1.18 96 16 96 16 110/68 124/86 1 430 
24 ABCD 24 45 F 534 4 94 136/84 1.26 105 11 105 11 130/90 148/90 4 428 
25 ABCD 25 48 M 509 3 70 110/70 1.22 86 16 89 19 110/70 120/88 0 431 
26 ABCD 26 39 M 672 6 80 120/70 1.18 96 16 98 18 110/70 124/86 1 423 
  
S. 
NO. 
ID.N0 
AGE 
(Yrs) 
SEX 
OP/IP 
NO 
DURATION OF 
DIABETES (Yrs) 
PULSE 
RATE (bpm) 
BP (mm Hg ) 
VALSALVA 
RATIO 
HRV TO 
DEEP 
BREATHING 
DIFFERENCE 
HRV FROM 
SUPINE TO 
STANDING 
DIFFERENCE 
BP 
RESPONSE 
TO STANDING 
BP RESPONSE 
TO SUSTAINED 
HAND GRIP 
CAN 
SCORE 
QT c 
27 ABCD 27 45 M 345 14 80 130/80 1.16 86 6 88 8 120/78 140/92 6 426 
28 ABCD 28 47 F 458 2 84 110/74 1.24 96 12 102 18 110/70 120/90 1 433 
29 ABCD 29 32 M 784 8 70 110/70 1.22 88 18 86 16 106/70 120/90 0 432 
30 ABCD 30 43 F 670 11 74 130/82 1.17 90 16 91 17 130/78 130/96 2 424 
31 ABCD 31 35 M 643 1 84 110/74 1.24 96 12 102 18 110/70 120/90 1 420 
32 ABCD 32 46 F 834 6 70 120/80 1.11 74 4 72 2 110/70 130/92 6 452 
33 ABCD 33 31 M 692 2 84 110/74 1.24 96 12 102 18 110/70 120/90 1 446 
34 ABCD 34 28 M 340 1 74 130/82 1.17 90 16 91 17 130/78 130/96 2 426 
35 ABCD 35 52 M 684 12 80 120/70 1.18 97 17 96 16 110/70 124/86 1 418 
36 ABCD 36 56 M 549 7 92 120/74 1.38 99 7 100 8 116/82 124/90 4 446 
37 ABCD 37 44 M 810 3 84 110/74 1.24 96 12 102 18 110/70 120/90 1 428 
38 ABCD 38 36 M 954 3 70 110/70 1.24 86 16 88 18 110/70 120/90 0 448 
39 ABCD 39 38 F 837 4 80 120/70 1.17 96 16 98 18 110/68 124/86 1 436 
40 ABCD 40 41 M 497 9 84 110/74 1.24 98 14 102 18 110/70 120/94 1 426 
41 ABCD 41 41 F 237 15 78 120/76 1.14 84 6 87 9 110/70 130/90 6 424 
42 ABCD 42 36 M 354 2 70 110/70 1.22 86 16 89 19 110/70 120/88 0 446 
43 ABCD 43 58 F 498 5 84 110/74 1.24 96 12 102 18 110/70 120/90 1 428 
44 ABCD 44 58 M 453 6 78 130/80 1.24 98 20 92 14 126/80 140/96 1 432 
45 ABCD 45 32 F 637 18 88 110/80 1.16 92 4 96 8 100/76 120/94 6 458 
46 ABCD 46 45 M 659 4 84 110/74 1.24 96 12 102 18 110/70 120/90 1 444 
47 ABCD 47 48 F 854 9 75 130/80 1.08 81 6 78 3 130/76 144/90 7 454 
48 ABCD 48 33 M 643 2 80 120/70 1.17 96 16 98 18 110/68 124/86 1 436 
49 ABCD 49 45 F 733 8 92 120/74 1.38 99 7 100 8 116/82 124/90 4 448 
50 ABCD 50 48 F 593 5 84 110/74 1.24 86 2 92 8 110/70 120/90 1 442 
51 ABCD 51 47 M 742 5 78 130/80 1.26 96 18 91 13 126/80 140/96 1 422 
52 ABCD 52 56 M 890 7 70 110/70 1.22 88 18 90 20 110/70 120/92 0 416 
  
S. 
NO. 
ID.N0 
AGE 
(Yrs) 
SEX 
OP/IP 
NO 
DURATION OF 
DIABETES (Yrs) 
PULSE 
RATE (bpm) 
BP (mm Hg ) 
VALSALVA 
RATIO 
HRV TO 
DEEP 
BREATHING 
DIFFERENCE 
HRV FROM 
SUPINE TO 
STANDING 
DIFFERENCE 
BP 
RESPONSE 
TO STANDING 
BP RESPONSE 
TO SUSTAINED 
HAND GRIP 
CAN 
SCORE 
QT c 
53 ABCD 53 38 F 957 18 80 120/84 1.19 84 4 90 10 110/80 130/96 3 424 
54 ABCD 54 32 M 874 1 78 130/80 1.26 96 18 91 13 126/80 140/96 1 418 
55 ABCD 55 46 F 674 6 84 110/74 1.24 98 14 102 18 110/70 120/94 1 452 
56 ABCD 56 48 M 693 4 88 100/70 1.13 97 9 106 18 100/68 110/86 3 444 
57 ABCD 57 45 M 489 3 84 110/74 1.24 96 12 102 18 110/70 120/90 1 432 
58 ABCD 58 42 M 769 2 80 120/70 1.18 96 16 96 16 110/68 124/86 1 422 
59 ABCD 59 42 F 701 14 92 120/74 1.38 99 7 100 8 116/82 124/90 3 426 
60 ABCD 60 43 M 492 9 103 118/80 1.12 110 7 107 4 120/80 120/84 7 448 
61 ABCD 61 45 F 307 4 84 110/74 1.24 86 2 92 8 110/70 120/90 1 418 
62 ABCD 62 38 M 636 3 78 120/76 1.14 84 6 87 9 110/70 130/90 6 452 
63 ABCD 63 49 F 665 15 78 130/80 1.26 96 18 91 13 126/80 140/96 1 448 
64 ABCD 64 49 M 987 8 76 110/74 1.23 92 16 94 18 106/70 110/96 1 426 
65 ABCD 65 42 M 765 2 78 130/80 1.26 96 18 91 13 126/80 140/96 1 418 
66 ABCD 66 48 M 873 4 80 120/70 1.18 96 16 96 16 110/68 124/86 1 422 
67 ABCD 67 37 F 902 6 70 110/70 1.22 86 16 88 18 110/70 120/90 0 436 
68 ABCD 68 33 M 761 1 70 110/70 1.22 86 16 89 19 110/70 120/88 0 446 
69 ABCD 69 45 M 392 18 84 110/74 1.24 96 12 102 18 110/70 120/90 1 416 
70 ABCD 70 44 F 739 3 80 120/70 1.18 96 16 96 16 110/68 124/86 1 424 
71 ABCD 71 50 M 843 8 80 130/80 1.16 86 6 88 8 120/78 140/92 6 458 
72 ABCD 72 42 F 456 2 80 120/70 1.18 97 17 96 16 110/70 124/86 1 422 
73 ABCD 73 37 M 721 6 76 110/74 1.23 90 14 94 18 106/70 110/92 1 432 
74 ABCD 74 49 M 429 5 80 120/70 1.18 97 17 96 16 110/70 124/86 1 444 
75 ABCD 75 33 F 465 3 70 11//76 1.23 86 16 89 19 110/70 120/88 0 416 
76 ABCD 76 36 M 842 2 78 130/80 1.26 96 18 91 13 126/80 140/96 1 422 
77 ABCD 77 48 F 683 9 74 130/82 1.17 90 16 91 17 130/78 130/96 2 414 
78 ABCD 78 44 F 640 4 80 120/70 1.17 96 16 98 18 110/68 124/86 1 426 
  
S. 
NO. 
ID.N0 
AGE 
(Yrs) 
SEX 
OP/IP 
NO 
DURATION OF 
DIABETES (Yrs) 
PULSE 
RATE (bpm) 
BP (mm Hg ) 
VALSALVA 
RATIO 
HRV TO 
DEEP 
BREATHING 
DIFFERENCE 
HRV FROM 
SUPINE TO 
STANDING 
DIFFERENCE 
BP 
RESPONSE 
TO STANDING 
BP RESPONSE 
TO SUSTAINED 
HAND GRIP 
CAN 
SCORE 
QT c 
79 ABCD 79 42 M 805 2 80 120/84 1.19 84 4 90 10 110/80 130/96 3 412 
80 ABCD 80 43 F 786 22 76 110/74 1.23 90 14 94 18 106/70 110/92 1 428 
81 ABCD 81 46 M 654 6 80 120/70 1.18 97 17 96 16 110/70 124/86 1 432 
82 ABCD 82 48 F 666 5 78 130/80 1.26 96 18 91 13 126/80 140/96 1 418 
83 ABCD 83 34 M 386 3 78 110/80 1.14 98 20 96 18 110/68 124/86 1 442 
84 ABCD 84 27 M 333 8 70 110/70 1.22 86 16 89 19 110/70 120/88 0 426 
85 ABCD 85 56 F 308 5 78 130/80 1.26 96 18 91 13 126/80 140/96 1 422 
86 ABCD 86 37 F 620 2 80 120/70 1.18 97 17 96 16 110/70 124/86 1 424 
87 ABCD 87 45 M 689 2 92 120/74 1.38 99 7 100 8 116/82 124/90 4 426 
88 ABCD 88 45 F 679 3 92 120/74 1.38 99 7 100 8 116/82 124/90 3 420 
89 ABCD 89 38 M 502 3 74 130/82 1.17 90 16 91 17 130/78 130/96 2 416 
90 ABCD 90 42 M 239 6 84 110/74 1.24 86 2 92 8 110/70 120/90 1 410 
91 ABCD 91 32 F 678 1 80 120/70 1.18 97 17 96 16 110/70 124/86 1 448 
92 ABCD 92 47 M 321 4 70 110/70 1.22 86 16 88 18 110/70 120/90 0 417 
93 ABCD 93 44 F 397 7 78 130/80 1.26 96 18 91 13 126/80 140/96 1 418 
94 ABCD 94 38 F 278 3 92 120/74 1.38 99 7 100 8 116/82 124/90 3 418 
95 ABCD 95 44 M 481 4 80 130/80 1.16 86 6 88 8 120/78 140/92 6 452 
96 ABCD 96 45 M 909 3 80 120/70 1.18 96 16 98 18 110/70 124/86 1 424 
97 ABCD 97 35 F 691 9 74 130/82 1.17 90 16 91 17 130/78 130/96 2 422 
98 ABCD 98 42 M 639 2 70 110/70 1.24 86 16 88 18 110/70 120/90 0 426 
99 ABCD 99 42 F 425 4 80 120/70 1.18 96 16 96 16 110/68 124/86 1 444 
100 ABCD 100 48 M 688 8 103 118/80 1.12 110 7 107 4 120/80 120/84 7 448 
 
